Delivery Order SPE2DB22D2006-SPE2DB25FW3FV
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,393.02 to AmerisourceBergen Drug Corp for XYOSTED 100 MG/0.5 ML auto-injectors on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. XYOSTED is a testosterone replacement therapy medication delivered via auto-injector,...
- The Defense Logistics Agency awarded a delivery order valued at $3,659.06 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector supplies on August 4, 2025, with completion targeted for August 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania facility. XYOSTED is a testosterone replacement therapy auto-injector used in military and federal healthcare systems to...
- The Defense Logistics Agency awarded a $1,937.56 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 mL auto-injector supplies. This competitively awarded, non-set-aside contract was issued on July 23, 2025, with an ultimate completion date of July 24, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy product delivered via auto-injector, supporting the military...
- The Defense Logistics Agency awarded a delivery order valued at $1,293.84 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector units. The contract is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in the same municipality....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,646.02 to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 mL auto-injector units on July 25, 2025, with completion scheduled for July 28, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a competitive award under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Xyosted is a...
- The Defense Logistics Agency awarded a delivery order valued at $1,721.26 to AmerisourceBergen Drug Corp for 0.5 mL of Xyosted 100 mg/0.5 mL auto-injector on July 24, 2025, with an ultimate completion date of July 25, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating competitive award. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy...
- The Defense Logistics Agency awarded a $460,000 firm fixed price delivery order to Amerisourcebergen Drug Corporation for the supply of XYOSTED 75 MG/0.5 ML auto-injectors. The single award delivery order, issued under an unspecified government-wide acquisition contract, calls for Amerisourcebergen to deliver 0.5mL auto-injectors of XYOSTED, a testosterone replacement drug, to a location in Conshohocken, Pennsylvania by August 9, 2023 to support the Department of Defense's medical supply...
- The Defense Logistics Agency awarded a delivery order valued at $1,655.80 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector units on July 28, 2025, with completion expected by July 29, 2025. This delivery order represents a firm fixed-price purchase with no set-aside designation, indicating the award was made through open competition. The pharmaceutical product will be delivered to the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- This delivery order, awarded July 28, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides Xyosted 100 mg/0.5 mL auto-injector pharmaceutical supplies with a ceiling value of $1,092.55. The contract utilizes firm fixed pricing and is scheduled for completion by July 29, 2025. As a non-set-aside, competitively awarded delivery order, this award represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA. The place of...
- The Defense Logistics Agency Troop Support Medical awarded a $406,300 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 4561375566 XYOSTED 50 MG/0.5 ML auto-injectors. The place of performance is Conshohocken, Pennsylvania. The period of performance is from June 29, 2023 through June 30, 2023. This delivery order was issued against an existing prime vendor contract vehicle to supply XYOSTED, a testosterone replacement therapy medication, to support the medical readiness...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW3FVDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $9,864.56 to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 ml auto-injector supplies. This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by August 11, 2025. The work will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. XYOSTED is a testosterone replacement therapy product delivered via auto-injector, supporting the Defense Health Agency's pharmaceutical supply requirements for military personnel and beneficiaries. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 comprehensive global pharmaceutical support vehicle valued through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen Drug Corp regularly fulfills diverse pharmaceutical and medical supply requirements for military healthcare systems. The company's extensive portfolio with DLA encompasses brand-name and generic medications, specialty pharmaceuticals, vaccines, and medical devices across multiple therapeutic areas, positioning it as a primary supplier for federal military and veteran healthcare procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.9k | 8/8/25 |